Erdmann Dirk, Zimmermann Catherine, Fontana Patrizia, Hau Jean-Christophe, De Pover Alain, Chène Patrick
Druggability Enzymology Profiling Unit, Novartis Institutes for BioMedical Research, Oncology, Novartis Pharma AG, Basel, Switzerland.
J Biomol Tech. 2010 Apr;21(1):9-17.
Protein kinases can adopt multiple protein conformations depending on their activation status. Recently, in drug discovery, a paradigm shift has been initiated, moving from inhibition of fully activated, phosphorylated kinases to targeting the inactive, unphosphorylated forms. For identification and characterization of putative inhibitors, also interacting with the latent kinase conformation outside of the kinase domain, highly purified and homogeneous protein preparations of unphosphorylated kinases are essential. The kinetic parameters of nonphosphorylated kinases cannot be assessed easily by standard kinase enzyme assays as a result of their intrinsic autophosphorylation activity. Kinetic binding rate constants of inhibitor-protein interactions can be measured by biophysical means upon protein immobilization on chips. Protein immobilization can be achieved under mild conditions by binding biotinylated proteins to streptavidin-coated chips, exploiting the strong and highly specific streptavidin-biotin interaction. In the work reported here, the cytoplasmic domains of insulin receptor and insulin-like growth factor-1 receptor fused to a biotin ligase recognition sequence were coexpressed individually with the phosphatase YopH and the biotin-protein ligase BirA upon triple infection in insect cells. Tandem affinity purification yielded pure cytoplasmic kinase domains as judged by gel electrophoresis and HPLC. Liquid chromatography-mass spectrometry analysis showed the absence of any protein phosphorylation. Coexpression of BirA led to quantitative and site-specific biotinylation of the kinases, which had no influence on the catalytic activity of the kinases, as demonstrated by the identical phosphorylation pattern upon autoactivation and by enzymatic assay. This coexpression approach should be applicable to other protein kinases as well and should greatly facilitate the production of protein kinases in their phosphorylated and unphosphorylated state suitable for enzymatic and biophysical studies.
蛋白激酶可根据其激活状态呈现多种蛋白质构象。最近,在药物研发领域已开始出现一种范式转变,即从抑制完全激活的磷酸化激酶转向靶向无活性的未磷酸化形式。为了鉴定和表征可能的抑制剂,这些抑制剂还与激酶结构域之外的潜在激酶构象相互作用,未磷酸化激酶的高度纯化且均一的蛋白质制剂至关重要。由于非磷酸化激酶具有内在的自磷酸化活性,因此无法通过标准激酶酶测定法轻松评估其动力学参数。抑制剂 - 蛋白质相互作用的动力学结合速率常数可在蛋白质固定在芯片上后通过生物物理方法进行测量。通过利用生物素化蛋白质与链霉亲和素包被芯片之间强且高度特异性的链霉亲和素 - 生物素相互作用,可在温和条件下实现蛋白质固定。在本文报道的工作中,与生物素连接酶识别序列融合的胰岛素受体和胰岛素样生长因子 -1 受体的细胞质结构域在昆虫细胞中进行三重感染时,分别与磷酸酶 YopH 和生物素 - 蛋白质连接酶 BirA 共表达。通过凝胶电泳和高效液相色谱法判断,串联亲和纯化产生了纯的细胞质激酶结构域。液相色谱 - 质谱分析表明不存在任何蛋白质磷酸化。BirA 的共表达导致激酶的定量和位点特异性生物素化,这对激酶的催化活性没有影响,自动激活时相同的磷酸化模式以及酶测定均证明了这一点。这种共表达方法也应适用于其他蛋白激酶,并应极大地促进适合酶学和生物物理研究的磷酸化和未磷酸化状态的蛋白激酶的生产。